This inventor holds 3 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 3 EPO patents. Top assignees: Cellis Ag, Cellis Sp. Z O.o. [Ltd.], Glanotech Limited. Active years: 2020-2025.
Company Filing History:
1 out of 1 
1 out of 1 
1 out of 1 Years Active: 2020-2025
Title: The Innovative Contributions of Alberto Boffi
Introduction
Alberto Boffi is a notable inventor based in Rome, Italy. He has made significant contributions to the field of cellular targeted delivery systems, with a focus on therapeutic applications, particularly in cancer treatment. His innovative work has led to the development of several patents that showcase his expertise and dedication to advancing medical technology.
Latest Patents
Alberto Boffi holds 3 patents, with his latest invention being a Cellular Targeted Label Delivery System. This invention relates to an isolated cellular targeted delivery system that comprises a CD45 leukocyte cell. Within this cell, a complex of one or more iron-binding proteins and an active ingredient is included. The methods for producing such an isolated cellular targeted delivery system and its uses for therapy, especially for cancer treatment, highlight the potential impact of his work in the medical field.
Career Highlights
Throughout his career, Alberto Boffi has worked with various companies, including Cellis Sp. Z O.o. and Cellis AG. His experience in these organizations has allowed him to collaborate with other professionals and contribute to groundbreaking research and development in his field.
Collaborations
Alberto has collaborated with notable coworkers such as Paola Baiocco and Irene Benni. Their joint efforts have further enhanced the innovative projects they have undertaken together.
Conclusion
Alberto Boffi's contributions to the field of cellular targeted delivery systems demonstrate his commitment to innovation and improving therapeutic methods for cancer treatment. His patents and collaborations reflect a significant impact on medical technology, paving the way for future advancements.